Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New migraine prevention pill EVO756 enters Mid-Stage trial

NCT ID NCT07616128

Prevention Sponsor: Evommune, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 04, 2026 · Updated 7 times

Summary

This Phase 2 study tests whether a daily pill called EVO756 can prevent migraines in adults who have not had success with other preventive treatments. About 330 participants will receive either EVO756 or a placebo, and researchers will track how many migraine days they have each month. The goal is to see if EVO756 safely reduces migraine frequency.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EVO756 (daily oral pill)
What this could lead to
If it works, this could offer a new daily pill to prevent migraines for people who haven't had success with other treatments.
What could go wrong
This is an early Phase 2 trial with only 330 people, so results may not hold up in larger studies. The drug may not reduce migraines better than a placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 330 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Adults aged 18 to \<65 years * Migraine with or without aura, per ICHD-3 criteria * History of failure with prior preventive migraine treatments * Not currently using migraine preventive therapy Key Exclusion Criteria: * Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders * Use of certain medications * Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder migraine with aura migraine without aura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    26 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Accel Research Site-Decatur-Alcanza

    RECRUITING

    Decatur, Georgia, 30030, United States

  • Apple Medical Research Group, Inc

    RECRUITING

    Miami, Florida, 331216, United States

    Contact Email: •••••@•••••

  • Asheville Neurology Specialists, Pa

    RECRUITING

    Asheville, North Carolina, 28806, United States

  • Bio Behavoural health

    RECRUITING

    Toms River, New Jersey, 08755, United States

  • Blessed Healthcase & Research

    RECRUITING

    Miami, Florida, 33173, United States

  • Buena Park Research Center

    RECRUITING

    Buena Park, California, 90620, United States

    Contact Email: •••••@•••••

  • CA Medical Clinic for Headache

    RECRUITING

    Los Angeles, California, 90067, United States

  • Clinical Neuroscience Solutions, Inc.

    RECRUITING

    Jacksonville, Florida, 32256, United States

  • Clinical Neuroscience Solutions, Inc.

    RECRUITING

    Orlando, Florida, 32819, United States

    Contact Email: •••••@•••••

  • Clinical Trials of South Carolina

    RECRUITING

    Charleston, South Carolina, 29406, United States

    Contact Email: •••••@•••••

  • Clinosis - Dent Neurologic Instite

    RECRUITING

    Amherst, New York, 14226, United States

  • Diablo Clinical Research dba Flourish Research

    RECRUITING

    Walnut Creek, California, 94598, United States

  • Eximia Research NC

    RECRUITING

    Raleigh, North Carolina, 27607, United States

  • Florida Research Center, Inc.

    RECRUITING

    Miami, Florida, 33174, United States

    Contact Email: •••••@•••••

  • FutureSearch Trials of Dallas

    RECRUITING

    Dallas, Texas, 75251, United States

  • FutureSearch Trials of Neurology

    RECRUITING

    Austin, Texas, 78731, United States

    Contact Email: •••••@•••••

  • Mass Institute of Clinical Research

    RECRUITING

    Westborough, Massachusetts, 01581, United States

  • Michigan Headache and Neurological Institute

    RECRUITING

    Ann Arbor, Michigan, 48104, United States

  • Neuro Pain Research Center

    RECRUITING

    Fresno, California, 93710, United States

  • New England Institute for Neurology and Headache

    RECRUITING

    Stamford, Connecticut, 06905, United States

  • Premiere Research Institute at Palm Beach Neurology

    RECRUITING

    West Palm Beach, Florida, 33407, United States

  • Quest Research Institute-Alcanza

    RECRUITING

    Farmington Hills, Michigan, 48334, United States

  • SFF Medical Research Group LLC

    RECRUITING

    Houston, Texas, 77018, United States

  • Trialsphere Corp

    RECRUITING

    Chandler, Arizona, 85286, United States

  • Vantage Clinical Trials

    RECRUITING

    Tampa, Florida, 33614, United States

  • Vaught Neurological Services

    RECRUITING

    Crab Orchard, West Virginia, 25827, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.